Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation...

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Targeted protein degradation (TPD) is a key strategy in cancer therapy, aiming to eliminate cancer's root causes and circumvent drug resistance.
• Proteolysis targeting chimeras (PROTACs) leverage the ubiquitin-proteasome system (UPS) to degrade target proteins within tumor cells.
• While PROTACs primarily target intracellular proteins, membrane protein degradation (e.g., EGFR, ALK, PD-L1, GPCR) has also been achieved.

Purpose of the Study:

• To review and discuss emerging membrane protein degradation techniques.
• To analyze the advantages, disadvantages, and potential applications of these novel strategies.
• To provide insights for developing future general membrane protein degradation methods.

Main Methods:

• Review of scientific literature on targeted protein degradation techniques.
• Analysis of PROTACs and related emerging strategies (AbTAC, LYTAC, molecular glues, Nano-PROTAC).
• Discussion of the mechanisms, benefits, and limitations of each technique.

Main Results:

• PROTACs and other TPD strategies can effectively degrade various membrane proteins implicated in cancer.
• Emerging techniques like antibody-based PROTACs (AbTACs), lysosome targeting chimeras (LYTACs), molecular glues, and nanoparticle-based PROTACs (Nano-PROTACs) offer alternative degradation pathways.
• Each method presents unique advantages and disadvantages regarding target specificity, efficiency, and delivery.

Conclusions:

• Membrane protein degradation is a promising therapeutic avenue in oncology.
• Diverse TPD strategies are being developed to target challenging membrane proteins.
• Further research into these techniques will likely lead to more effective and generalizable cancer therapies.